Journal
EJSO
Volume 48, Issue 8, Pages 1723-1729Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.ejso.2022.01.003
Keywords
Sarcoma; Myxo fibrosarcoma; Local recurrence; Survival; Chemotherapy; Radiotherapy
Ask authors/readers for more resources
This study analyzed the histopathologic margins, perioperative treatments, and patient outcomes in primary myxofibrosarcoma (MFS) patients. The status of histopathologic margins, tumor grade, and size were found to independently predict local recurrence, distant metastasis, and overall survival in MFS patients.
Background: this study analysed primary myxofibrosarcoma (MFS) to investigate patient outcomes focusing on histopathologic margins and perioperative treatments.Patients and methods: data from consecutive patients affected by primary and localized MFS of the ex-tremities or trunk wall who underwent surgery (2002-2017) were analysed. Local recurrence (LR), amputation rate, incidence of distant metastasis (DM), and overall survival (OS) were studied.Results: Of 293 included patients, 52 (17%) patients received perioperative treatments and 54 (18%) had positive microscopic histopathologic margins (R1). Median follow-up was 80 months (IQR, 49-109). 5-yr CCI of LR was 0.12 (SE: 0.02). Status of histopathologic margins (P < 0.001), tumour malignancy grade (P = 0.018) and size (P = 0023) were independent prognostic factor for LR. Nine amputations (ampu-tation rate: 3%) were performed (N =1 for primary tumour; N = 8 for LR). Larger tumour size (P = 0.015) and higher grade (P = 0.025) were independent prognostic factor for DM. 5-year OS was 0.84 (95%CI 0.79-0.88). Patient age (P = 0.008), tumour size (P = 0.013) and malignancy grade (P = 0.018) were inde-pendently associated to OS. In the subgroup of patients who had a re-excision for a primary MFS (N = 116, 40%), the presence of residual disease was not associated with LR, DM, or OS.Conclusion: in this study 5-year LR, DM and OS were 12%, 17%, and 84%, respectively. One in six patients had a positive surgical margin, which was a prognostic factor for LR, while DM and OS were predicted by tumour grade and size. Findings from this large patient cohort may set benchmarks for investigating new treatment options for MFS.(c) 2022 Elsevier Ltd, BASO -The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available